Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;21(5):392-402.
doi: 10.1136/practneurol-2020-002782. Epub 2021 Jun 9.

Trigeminal neuralgia: a practical guide

Affiliations
Review

Trigeminal neuralgia: a practical guide

Giorgio Lambru et al. Pract Neurol. 2021 Oct.

Abstract

Trigeminal neuralgia (TN) is a highly disabling disorder characterised by very severe, brief and electric shock like recurrent episodes of facial pain. New diagnostic criteria, which subclassify TN on the basis of presence of trigeminal neurovascular conflict or an underlying neurological disorder, should be used as they allow better characterisation of patients and help in decision-making regarding medical and surgical treatments. MR imaging, including high-resolution trigeminal sequences, should be performed as part of the diagnostic work-up. Carbamazepine and oxcarbazepine are drugs of first choice. Lamotrigine, gabapentin, pregabalin, botulinum toxin type A and baclofen can be used either alone or as add-on therapy. Surgery should be considered if the pain is poorly controlled or the medical treatments are poorly tolerated. Trigeminal microvascular decompression is the first-line surgery in patients with trigeminal neurovascular conflict while neuroablative surgical treatments can be offered if MR imaging does not show any neurovascular contact or where patients are considered too frail for microvascular decompression or do not wish to take the risk.

Keywords: headache; pain; trigeminal nerve; trigeminal neuralgia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: GL has received speaker honoraria, funding for travel and has received honoraria for participation in advisory boards sponsored by Allergan, Novartis, Eli Lilly and TEVA. He has received speaker honoraria, funding for travel from electroCore, Nevro Corp and Autonomic Technologies. JZ serves on the advisory board of Biogen and Eli Lilly and received payment from Biogen for design of drug trials. MM serves on the advisory board for Abbott, Allergan, Eli Lilly, Medtronic, Novartis and TEVA, and has received payment for the development of educational presentations from Allergan, electroCore, Eli Lilly, Novartis and TEVA.

Figures

Figure 1
Figure 1
International Classification of Headache Disorders Edition 3 subclassification of trigeminal neuralgia.
Figure 2
Figure 2
MR scan of the trigeminal nerve and intraoperative pictures during microvascular decompression in patient with classical trigeminal neuralgia. (A) Axial MR 0.5 mm volumetric SPACE sequence through the pons showing neurovascular conflict between the right superior cerebellar artery (SCA) and the right trigeminal nerve (V). (B) Intraoperative view of the right cerebellopontine angle, prior to right microvascular decompression, showing conflict between the right SCA and V. (C) Black and white rendition of the previous photograph with labelling of the superior cerebellar artery, V, and more superficial seventh and eighth nerve complex (VII/VIII). (D) The superior cerebellar artery has been mobilised and transposed superiorly towards the tentorium. It is held in place with a small piece of Teflon (T). (E) A small drop of fibrin glue (F) has been applied to ensure that the T does not migrate. A small ‘dent’ in the course of the trigeminal nerve can be seen at the site of the previous neurovascular conflict. SPACE, sampling perfection with application optimised contrasts using different flip angle evolution.
Figure 3
Figure 3
Proposed algorithm for the treatment of trigeminal neuralgia. *Microvascular decompression (MVD) appears effective even in idiopathic TN and may be more effective than stereotactic radiosurgery. **If any of carbamazepine, oxcarbazepine, lamotrigine, gabapentin or pregabalin have not been tried then trials of these agents should be considered. ***Internal neurolysis is best avoided after MVD as there is a suggestion that there is a higher risk of anaesthesia dolorosa. ****Consider MVD if the secondary cause is optimally treated and there is evidence of neurovascular conflict; exercise caution in MS with ipsilateral pontine plaque. MS, multiple sclerosis; TN, trigeminal neuralgia.

References

    1. Zakrzewska JM, Wu J, Mon-Williams M, et al. . Evaluating the impact of trigeminal neuralgia. Pain 2017;158:1166–74. 10.1097/j.pain.0000000000000853 - DOI - PubMed
    1. Sjaastad O, Bakketeig LS. The rare, unilateral headaches. Vågå study of headache epidemiology. J Headache Pain 2007;8:19–27. 10.1007/s10194-006-0292-4 - DOI - PMC - PubMed
    1. Mueller D, Obermann M, Yoon M-S, et al. . Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia 2011;31:1542–8. 10.1177/0333102411424619 - DOI - PubMed
    1. Koopman JSHA, Dieleman JP, Huygen FJ, et al. . Incidence of facial pain in the general population. Pain 2009;147:122–7. 10.1016/j.pain.2009.08.023 - DOI - PubMed
    1. Katusic S, Beard CM, Bergstralh E, et al. . Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol 1990;27:89–95. 10.1002/ana.410270114 - DOI - PubMed

MeSH terms